Skip to main content

Advertisement

SpringerLink
Log in

Hypersensitivity reactions to oxaliplatin and other antineoplastic agents

  • Published:
Current Allergy and Asthma Reports Aims and scope Submit manuscript

Abstract

Although the reported incidence of hypersensitivity reactions (HSR) to antineoplastic agents is considered to be uncommon, it is difficult to evaluate their exact prevalence, mainly because their definition is vast and pathogenic mechanisms are vague. HSR include facial flushing, erythema, pruritus, fever, tachycardia, dyspnea, tongue swelling, rash/hives, headache, chills, weakness, vomiting, burning sensations, dizziness, and edema. Treatment and prevention consists of slowing the infusion rate, steroids, and type 1 and 2 histamine receptor antagonists. Desensitization could allow the small number of patients who experience severe HSR to receive effective therapy for their cancer. Reintroductions have only been reported as single case studies or small cohorts. Large-scale validation on desensitization strategies is still missing. With regard to oxaliplatin, knowledge of its rare but eminent toxicity is paramount, because this drug is widely used in treating colorectal cancer, the second-highest cause of cancer mortality in the United States.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Shepherd GM: Hypersensitivity reactions to chemotherapeutic drugs. Clin Rev Allergy Immunol 2003, 24:253–262.

    Article  PubMed  CAS  Google Scholar 

  2. Robinson JB, Singh D, Bodurka-Bevers DC, et al.: Hypersensitivity reactions and the utility of oral and intravenous desensitization in patients with gynecologic malignancies. Gynecol Oncol 2001, 82:550–558.

    Article  PubMed  CAS  Google Scholar 

  3. Gruchalla RS: Drug allergy. J Allergy Clin Immunol 2003, 111(2 Suppl):S548–S559.

    Article  PubMed  CAS  Google Scholar 

  4. Rothenberg ML, Oza AM, Bigelow RH, et al.: Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol 2003, 21:2059–2069.

    Article  PubMed  CAS  Google Scholar 

  5. De Gramont A, Banzi M, Navarro M, et al.: Oxaliplatin/5-FU/LV in adjuvant colon cancer: results of the international randomized mosaic trial. Proc Am Soc Clin Oncol 2003, 22:253.

    Google Scholar 

  6. Maindrault-Goebel F, Andre T, Tournigand C, et al.: Allergic-type reactions to oxaliplatin: retrospective analysis of 42 patients. Eur J Cancer 2005, 41:2262–2267.

    Article  PubMed  CAS  Google Scholar 

  7. Thomas RR, Quinn MG, Schuler B, et al.: Hypersensitivity and idiosyncratic reactions to oxaliplatin. Cancer 2003, 97:2301–2307.

    Article  PubMed  Google Scholar 

  8. De Vries RS, Mattijssen EJ, van Sorge AA: Serious delayed hypersensitivity reaction to oxaliplatin. Ann Oncol 2006, 17:1723–1724.

    Article  PubMed  Google Scholar 

  9. Stahl M, Koster W, Wilke H: Reaction after oxaliplatin-prevention with corticosteroids. Ann Oncol 2005, 12:874.

    Article  Google Scholar 

  10. Santini D, Tonini G, Salerno A, et al.: Idiosyncratic reactions after oxaliplatin infusion. Ann Oncol 2005, 12:132–133.

    Article  Google Scholar 

  11. Newman Taylor AJ, Cullinan P, Lympany PA, et al.: Interaction of HLA phenotype and exposure intensity in sensitization to complex platinum salts. Am J Resp Crit Care Med 1991, 160:435–438.

    Google Scholar 

  12. Hetherington S, Hughes AR, Mosteller M, et al.: Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet 2002, 359:1121–1122.

    Article  PubMed  CAS  Google Scholar 

  13. Bhargava P, Gammon D, McCormick MJ: Hypersensitivity and idiosyncratic reactions to oxaliplatin. Cancer 2004, 100:211–212.

    Article  PubMed  Google Scholar 

  14. Brandi G, Pantaleo MA, Galli C, et al.: Hypersensitivity reactions related to oxaliplatin (OHP). Br J Cancer 2003, 89:477–481.

    Article  PubMed  CAS  Google Scholar 

  15. Meyer L, Zuberbier T, Worm M, et al.: Hypersensitivity reactions to oxaliplatin: cross-reactivity to carboplatin and the introduction of a desensitization schedule. J Clin Oncol 2002, 20:1146–1147.

    PubMed  Google Scholar 

  16. Qureshi KM: Incidence of hypersensitivity reactions to oxaliplatin at Roswell Park Cancer Institute (RPCI) and protocol for desensitization. Proc Am Soc Clin Oncol 2003, 22:789.

    Google Scholar 

  17. Siu SW, Chan RT, Au GK: Hypersensitivity reactions to oxaliplatin: experience in a single institute. Ann Oncol 2005, 17:259–261.

    Article  PubMed  Google Scholar 

  18. Lee MY, Yang MH, Liu JH, et al.: Severe anaphylactic reactions in patients receiving oxaliplatin therapy: a rare but potentially fatal complication. Support Care Cancer 2007, 15:89–93.

    Article  PubMed  Google Scholar 

  19. Eloxatin (oxaliplatin injection) [package insert]. Bridgewater, NJ: Sanofi Aventis US; 2007. Available at: www.eloxatin.com.

  20. Herrero T, Tornero P, Infante S, et al.: Diagnosis and management of hypersensitivity reactions caused by oxaliplatin. J Investig Allergol Clin Immunol 2006, 16:327–330.

    PubMed  CAS  Google Scholar 

  21. Ulrich-Pur H, Penz M, Fiebiger WC, et al.: Oxaliplatin-induced fever and release of IL-6. Oncology 2000, 59:187–189.

    Article  PubMed  CAS  Google Scholar 

  22. Sampson HA, Muñoz-Furlong A, Campbell RL, et al.: Second symposium on the definition and management of anaphylaxis: summary report—Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol 2006, 117:391–397.

    Article  PubMed  Google Scholar 

  23. Lenz HJ: Management and preparedness for infusion and hypersensitivity reactions. Oncologist 2007, 12:601–609.

    Article  PubMed  CAS  Google Scholar 

  24. Christina VT: Hypersensitivity reactions to oxaliplatin in two Asian patients. Ann Pharmacother 2005, 39:1114–1118.

    Article  Google Scholar 

  25. Zanotti KM, Markman M: Prevention and management of antineoplasticinduced hypersensitivity reactions. Drug Saf 2001, 24:767–779.

    Article  PubMed  CAS  Google Scholar 

  26. Gonzales ID, Saez RS, Rodilla EM, et al.: Hypersensitivity reactions to chemotherapy drugs. Alergol Immunol Clin 2000, 15:161–181.

    Google Scholar 

  27. Leguy-Seguin V, Jolimoy G, Coudert B, et al.: Diagnostic and predictive value of skin testing in platinum salt hypersensitivity. J Allergy Clin Immunol 2007, 119:726–730.

    Article  PubMed  CAS  Google Scholar 

  28. Zanotti K, Rybicki L, Kennedy A, et al.: Carboplatin skin testing: a skin-testing protocol for predicting hypersensitivity to carboplatin chemotherapy. J Clin Oncol 2001, 19:3126–3129.

    PubMed  CAS  Google Scholar 

  29. Markman M, Zanotti K, Peterson G, et al.: Expanded experience with an intradermal skin test to predict for the presence or absence of carboplatin hypersensitivity. J Clin Oncol 2003, 21:4611–4614.

    Article  PubMed  CAS  Google Scholar 

  30. Garufi C, Cristaudo A, Vanni B, et al.: Skin testing and hypersensitivity reactions to oxaliplatin. Ann Oncol 2003, 14:497–498.

    Article  PubMed  CAS  Google Scholar 

  31. Mis L, Fernando NH, Hurwitz HI, Morse MA: Successful desensitization to oxaliplatin. Ann Pharmacother 2005, 39:966–968.

    Article  PubMed  Google Scholar 

  32. Edmondson DA, Gruling BJ, Urmanski AM, et al.: Oxaliplatin hypersensitivity: case report and successful repeat desensitization. Am J Ther 2007, 14:116–118.

    Article  PubMed  Google Scholar 

  33. Saif MW, Reardon J: Management of oxaliplatin-induced peripheral neuropathy. Ther Clin Risk Manage 2005, 1:249–258.

    CAS  Google Scholar 

  34. Saif MW: Oral calcium ameliorating oxaliplatin-induced peripheral neuropathy. J Applied Res 2004, 4:576–582.

    Google Scholar 

  35. Saif MW: Hypersensitivity reactions associated with oxaliplatin. Expert Opin Drug Saf 2006, 5:687–694.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Section of Medical Oncology, Yale University School of Medicine, 333 Cedar Street, FMP:116, New Haven, CT, 06520, USA

    M. Wasif Saif

Authors
  1. Ekaterini Syrigou
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kostas Syrigos
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Wasif Saif
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. Wasif Saif.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Syrigou, E., Syrigos, K. & Saif, M.W. Hypersensitivity reactions to oxaliplatin and other antineoplastic agents. Curr Allergy Asthma Rep 8, 56–62 (2008). https://doi.org/10.1007/s11882-008-0011-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11882-008-0011-0

Keywords

Search

Navigation